4523 On Other Exchanges
4523 is not on other exchanges.

eisai co ltd (4523) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. The company offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer’s disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. It also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, the company offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. It has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

9,877 Employees
Last Reported Date: 06/17/16
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥142.0M
Senior Vice President, Chief Commercial Offic...
Total Annual Compensation: ¥130.0M
Vice President, President of Eisai Inc and Ch...
Total Annual Compensation: ¥81.0M
Vice President, Chief Clinical Officer of Neu...
Total Annual Compensation: ¥111.0M
Compensation as of Fiscal Year 2016.

eisai co ltd (4523) Key Developments

Eisai Co., Ltd. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016

Eisai Co., Ltd. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016 . Venue: Prince Park Tower Hotel, 4-8-1, Shibakoen, Minato-ku, Tokyo 105-8563, Japan.

Eisai Co., Ltd. Announces Anticancer Agent TREAKISYM for Injection 100 Mg for an Additional Indication of Chronic Lymphocytic Leukemia

Eisai Co., Ltd. announced that the anticancer agent TREAKISYM for Injection 100 mg has been approved in Japan for an additional indication of chronic lymphocytic leukemia. TREAKISYM is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals Limited. TREAKISYM was initially approved in Japan in October 2010 for relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma. Under the licensing agreement concluded between the two companies, Eisai has been marketing the product in Japan since its launch in December 2010. Symbio filed an application for this additional indication in December 2015 in response to a development request from the Japanese Ministry of Health, Labour and Welfare's Study Group on Unapproved and Off Label Drugs with high unmet medical needs. Chronic lymphocytic leukemia is a blood cancer characterized by neoplastic transformation and excess propagation of lymphocytes, a type of white blood cell, in the bone marrow. With approximately 2,000 patients with chronic lymphocytic leukemia in Japan as well as an incidence rate of new cases of approximately 0.3 in 100,000, this is a disease with high unmet medical need. Furthermore, TREAKISYM has been designated as an orphan drug for chronic lymphocytic leukemia in Japan.

Eisai Co., Ltd. to Launch New Drug for Mouth Ulcers in Japan

Eisai Co., Ltd. has announced that it will launch Chocola BB Mouth Ulcer Repair Shot, a third-class OTC drug, for mouth ulcers in Japan. The product is the first oral care spray to be marketed under the Chocola BB brand. Chocola BB Mouth Ulcer Repair Shot is a medicated spray that is effective for mouth ulcers and soothing pain caused by inflammation in the throat. Containing antiseptic cetylpyridinium chloride (CPC) that keeps the mouth clean, as well as azulene which acts to repair the mucous membrane, the spray alleviates the symptoms of mouth ulcers by allowing the active ingredients to be directly applied into the mouth. It also comes in a compact form making it portable and easy to use anywhere without having to directly touch the affected area. Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, and Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims).


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4523.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4523 Industry Range
Price/Earnings 26.7x
Price/Sales 3.4x
Price/Book 3.4x
Price/Cash Flow 25.9x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.